Physician profile
Fernanda Salgado
NPI 1093256349
$2,681.86
in general payments reported to CMS, 2019-2025
17 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.37 · 2022: $412 · 2023: $1,266 · 2024: $784 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.29 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.12 | 2021-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $448.33 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $418.50 | 2022-2024 | Dupixent |
| Strata Skin Sciences, INC. | $218.24 | 2022-2025 | Xtrac |
| Sun Pharmaceutical Industries INC. | $192.81 | 2022-2024 | Absorica Ld, Winlevi, Ilumya |
| Incyte Corporation | $145.73 | 2022-2024 | Opzelura |
| Pfizer INC. | $87.67 | 2023 | |
| Mayne Pharma Commercial LLC | $82.38 | 2023-2024 | |
| Cipher Pharmaceuticals US LLC | $74.07 | 2025 | Natroba, Spinosad |
| Lilly USA, LLC | $59.95 | 2023-2024 | Taltz, Ebglyss |
| Leo Pharma INC. | $58.05 | 2022-2023 | Adbry |
| Almirall LLC | $50.94 | 2022-2023 | Seysara |
| Journey Medical Corporation | $42.67 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $31.14 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $25.63 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $18.39 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $14.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernanda Salgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.